China’s WuXi, Johnson & Johnson-backed XW Labs lands $17.5M series B

The biotech is focused on mitochondria in relation to certain CNS disorders

Chinese neurological disorders startup XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.

The funding boost was led by Elements Capital and WI Harper, with help from new investor KTB Network, and all existing investors Kleiner Perkins Caufield & Byers China (KPCB China), Johnson & Johnson Innovation, and WuXi Venture.

XW Labs said in a statement that it will “utilize funds to continue the development of its multiple programs that are entering clinical and IND-enabling studies.”


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

It focuses on several areas: The first is targeting a boost to the safety profiles of existing meds, as well as potential new indications.

The other is a new platform focused on reducing damage to the mitochondria, the so-called “powerhouses of the cell,” which has been linked to a number of neurological disorders.

RELATED: Boosting a mitochondria-targeting protein could postpone aging

“Our company is entering a critical stage where we anticipate at least one program to enter clinical trials per year starting in 2018,” said Jia-Ning Xiang, founder and CEO of XW Labs.

More details on specific targets and MAOs were not given.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.